PRESS RELEASE



Amoéba informs about the postponement of the publication date
of its half-yearly accounts

Lyon (France), September 20th, 2019 - AMOEBA (FR0011051598 -AMEBA), producer of biological
biocides capable of eliminating bacterial risks in water and human wounds, and a biocontrol product
for plant protection, still in trial phase, announces the postponement of the closing of the half-yearly
accounts at June 30, 2019.



As the finalization of the financial statements is in progress, the Board of Directors, which met today,
decided to postpone the publication date for the half-yearly accounts from 20 September to 27
September 2019.




About AMOEBA:
Amoéba’s ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare
and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba
is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical
biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection
estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as
chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare,
biocides and crop protection are subject to the Company being granted local regulatory market authorizations.
The Company is currently in a trial phase for biocidal and plant protection applications and does not market any
products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba
is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence
network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-
biocide.com.
(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK




Contacts:

Amoéba Investors Relations Medias relations
Valérie FILIATRE Grégory BOSSON Constance LOZET
General Manager Agence Calyptus Agence Ekno
+33 (0)4 26 69 16 00 +33(0)1 53 65 37 90 +33(0)7 78 41 19 70
valerie.filiatre@amoeba-biocide.com gregory.bosson@calyptus.net constance.lozet@ekno.fr
Disclaimer
This press release contains certain forward-looking statements concerning AMOEBA which are based on its own
assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance
that the estimates contained in such forward-looking statements will be verified, which estimates are subject to
numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial
Markets Authority (Autorité des Marchés Financiers) on April 25, 2019 under number D19-0383 (a copy of which
is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are
also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence
of all or part of such risks could cause actual results, financial conditions, performance or achievements of
AMOEBA to be materially different from such forward-looking statements.